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Abstract This paper describes the rationale for the development of dual dopamine D2-receptor and I]2-adrenoceptor 
agonists as potential treatments for the symptoms of chronic obstructive pulmonary disease (COPD). The putative 
involvement of pulmonary sensory afferent nerves in mediating the key COPD symptoms of breathlessness, cough and 
excess sputum production is outlined and the hypothesis that activation of D2-receptors on such nerves would modulate 
their activity is developed. This premise was tested, in a range of animal models, using the first of a novel class of dual 
dopamine D2-receptor and I]2-adrenoceptor agonists, sibenadet HCI (Viozan TM, AR-C68397AA). In the course of these 
studies it was demonstrated that sibenadet, through activation of D2-receptors, inhibited discharge of rapidly adapting 
receptors and was effective in reducing reflex-induced tachypnoea, mucus production and cough in the dog. Sibenadet, 
through its activation of I]2-adrenoceptors, was also shown to be an effective bronchodilator with a prolonged duration 
of action following topical administration to the lungs. These studies also indicated that sibenadet had a wide therapeutic 
ratio with respect to expected undesirable side-effects such as emesis and cardiovascular disturbances. These results 
provided a compelling rationale for the initiation of a clinical development programme with sibenadet for the treatment 
of COPD. 
© 2003 Elsevier Science Ltd 
INTRODUCTION 
Pulmonary sensory nerves and their 
role in the pathophysiology of COPD 
Chronic obstructive pulmonary disease (COPD) is a 
growing worldwide public health issue and is predicted 
to become the third biggest cause of global mortality by 
2020 (I). It is, however, poorly treated (2) as a result of 
inadequate and limited treatment options. New therapies 
that reduce the symptoms of breathlessness, cough and 
excess sputum production, which are characteristic of 
this disease, would significantly improve the quality of life 
of patients. All these symptoms can potentially be 
mediated by neuronal mechanisms in that sensory 
afferent nerves, activated by endogenous and exogenous 
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irritants, can generate reflexes eliciting cough, mucus 
production, bronchoconstriction and changes in the 
depth of breathing (3). This leads to the hypothesis that 
modulation of sensory nerve activity would have 
therapeutic benefit in the treatment of lung diseases such 
as COPD. 
Afferent sensory information from the lung is mainly 
carried within the vagus nerve, the cell bodies of the 
fibres being found in either of two ganglia, the nodose 
and jugular located along the cervical vagus. The cell 
bodies of spinal afferent neurones innervating the 
airways are situated along the spinal cord. The 
importance of this sensory innervation is highlighted by 
findings such as those of Agostini et al. (4) who 
demonstrated that the majority of vagal fibres 
(approximately 80%) innervating cat bronchi are afferent 
in nature. Three major classes of sensory nerve fibres 
have been identified within the airways. Slowly adapting 
or 'stretch' receptors are associated with reflex control 
of breathing. These are myelinated afferent fibres located 
primarily in the smooth muscle, which elicit a long-lasting 
discharge of action potentials in response to, for 
example, prolonged and maintained lung inflation. They 
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are found throughout the lung, but are primarily 
concentrated in the large conducting airways. In the dog, 
approximately 50% of such receptors are thought to be 
located in the trachea (5). Rapidly adapting (RARs) or 
'irritant' receptors are myelinated afferent fibres that are 
sensitive to a variety of stimuli including chemical 
irritants such as histamine, as well as mechanical and 
osmotic stimuli (6). These are located along the length of 
the entire tracheobronchial tree, but again are found 
primarily in the larger airways (7). Activation of these 
RARs is thought to elicit defensive reflexes such as 
cough, mucus production and rapid shallow breathing (8). 
In the dog, cigarette smoke has also been shown to 
stimulate discharge from RARs (9). 
Finally, there are C-fibres, which have a high density in 
the airways and are thought to have a key role in the 
defence of the lower airways (10). These unmyelinated 
fibres can be further divided into two groups based upon 
their anatomical ocation, these being pulmonary C-fibres 
found in the peripheral airways and bronchial C-fibres 
found in the larger airways. Stimulation of C-fibres in 
dogs leads to a variety of defensive reflexes including 
cough, tachypnoea (I I), mucus secretion (12), apnoea 
and bronchoconstriction (10). Many C-fibres also 
contain a variety of neuropeptides in their peripheral 
processes and may therefore also cause axonal or local 
reflexes (I 3). 
Dopamine as a neuromodulator of 
pulmonary sensory nerves  
The dopaminergic system in the brain and its 
involvement in the pathophysiology of neurological and 
psychiatric disorders of the central nervous system has 
been the focus of a large body of research. In contrast 
the role of dopamine receptors in the peripheral 
nervous system has been less extensively studied. 
Nevertheless, a number of studies have indicated that 
dopamine has a role as a peripheral neurotransmitter 
and that it can modulate the activity of sensory nerves. 
For example, in anaesthetized cats, dopamine decreases 
the rate of nerve discharge from the carotid body 
chemoreceptors (14). 
Such findings suggest that dopamine could act to 
modulate the activity of sensory nerves in the lung. 
Indeed, dopamine receptor agonists and antagonists have 
been shown to have a number of effects on lung function 
in clinical studies. Inhalation of dopamine has been 
shown to inhibit histamine-induced bronchoconstriction 
in normal and asthmatic subjects (15), although it did not 
affect resting bronchomotor tone (16,17). In addition, 
inhalation of dopamine by asthmatic patients during an 
exacerbation induces bronchodilatation (I 7). 
There are also several case reports that the dopamine 
precursor levodopa can improve chronic bronchitis (18) 
and that the anti-psychotic haloperidol (a dopamine 
receptor antagonist) can produce bronchospasm (19). 
The interpretation of such studies is, however, 
complicated by the fact that dopamine (and the other 
agents used) has activity at a number of other receptors 
including both co- and ~-adrenoceptors. Nevertheless, an 
effect of dopamine on dopamine receptors cannot be 
totally excluded in these studies. 
Some of the strongest functional evidence that 
dopamine can modulate the activity of peripheral 
sensory nerves in the lung comes from studies in the 
dog. Jackson and Simpson (20) demonstrated that, in 
dogs pre-treated with propranolol and phentolamine (to 
block ~- and ~-adrenoceptor effects respectively), 
dopamine infusion inhibited the ability of histamine to 
stimulate RARs. This inhibition by dopamine was 
antagonized in animals treated with the selective D 2- 
receptor antagonist, sulpiride. Dopamine did not affect 
lung function, as measured by changes in resistance or 
compliance, suggesting that it was acting directly on 
sensory nerves rather than by preventing broncho- 
constriction, which would activate RARs by mechanical 
distortion. These observations thus provided direct 
evidence that dopamine is able to modulate the activity 
of sensory nerves. The premise that these effects were 
mediated by dopamine receptors of the D2-receptor 
subtype was strengthened by a number of reports in the 
literature indicating that D2-receptors (messenger RNA 
and/or the protein) are present in sensory ganglia 
(21-26,28). 
More recently it has been shown that selective D 2- 
receptor agonists can modulate the activity of sensory 
nerves both in vitro (27,28) and in vivo (29). In the in vitro 
studies, the selective D2-receptor agonist ropinirole was 
shown to inhibit the release of the neuropeptide 
calcitonin gene-related peptide from slices of dorsal 
spinal cord and airways of the guinea-pig following 
stimulation with 80 mM potassium chloride (27). The 
same agonist was also shown to inhibit mobilization of 
intracellular calcium in rat dorsal root ganglion cells 
following electrical stimulation (28). In both of these 
studies, the effects of ropinirole were blocked by 
sulpiride. The in vivo studies demonstrated that another 
selective D2-receptor agonist, quinpirole, inhibited 
prostaglandin E2-induced hyperresponsiveness of 
pulmonary C-fibres and ozone-induced tachypnoea in 
the rat (29). These effects of quinpirole were blocked by 
the selective D2-receptor antagonist domperidone. 
The rationale for designing dual D 2- 
receptor and 1~2-adrenoceptor agonists 
as drugs for the  t reatment  of COPD 
The body of evidence described above resulted in the 
initiation of a programme of work aimed at designing 
highly potent D2-receptor agonists. The ultimate goal 
was to test the hypothesis that stimulation of 
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Dz-receptors on sensory nerve endings in the airways 
would inhibit afferent activity and consequently suppress 
reflex mediated cough, sputum production and dyspnoea 
in patients with COPD, thus providing a novel treatment 
for the symptoms of this disease. 
As ~2-adrenoceptor agonists have found utility in the 
management of COPD, specifically in reducing breath- 
lessness, the possibility of designing drugs which also 
possessed this activity was explored.The primary thera- 
peutic effect of ~2-agonists is relaxation of airway 
smooth muscle, but they also have effects on inflam- 
matory processes (30-32) and on mucociliary activity 
(33) that may be important in alleviating COPD 
symptoms. Second-generation ~z-agonists, such as 
salmeterol and formoterol, have a clinical duration of 
action in excess of 12 hours (34) and therefore the aim 
was to design molecules that possessed a long duration 
of action at ~32-adrenoceptors (and D2-receptors ).
Accordingly, research efforts were focused on the 
identification of topically active compounds that exhibited 
potent agonism at both D2-receptors and [~2" 
adrenoceptors and that had a long duration of action. 
Sibenadet (4-hydroxy-7-[2-[2-[3-(2-phenylethoxy)propyl- 
sulphonyl]ethylamino]ethyl]- 1,3-benzothiazol-2(3 H)-one 
hydrochloride) (35) was one of the first such compounds 
identified during this programme of research and the 
pre-clinical findings with this compound are described 
below. 
RESULTS 
In vitro studies 
Detailed in vitro pharmacological profiling of sibenadet 
was performed using a range of isolated tissue systems 
and radioligand binding assays. These studies demon- 
strated that sibenadet was a potent [~2-adrenoceptor 
(ECs0 of 11.2 nM in guinea-pig trachea) and Dz-receptor 
agonist (ECs0 = I.I nM in rabbit ear artery) (36).The 
compound also showed good selectivity in that it was 
either inactive or had low activity at a range of other 
adrenoceptors (~3 I, 63, °el and cc2) and dopamine 
receptors (D I, D 4, Ds) although it also had high affinity 
for the dopamine D3-receptor (36). Sibenadet was also 
shown to have prolonged ~2 duration of action in the 
guinea-pig isolated, superfused trachea preparation 
exhibiting a recovery profile significantly longer than 
formoterol but shorter than salmeterol (37). 
In vivo studies 
The ability of the Dz-receptor agonist properties of 
sibenaclet o modulate sensory nerve driven processes 
has been examined in a number of animal models. 
Sibenadet (10 I~g kg- I, i.v.) inhibited histamine-induced 
discharge from RARs in ~-blocked dogs, an effect that 
was reversed by the D2-receptor antagonist, sulpiride 
(38). Given this finding, it was predicted that sibenadet 
would block reflex-induced responses in animal model 
systems. Histamine aerosols when given intratracheally 
to lightly anaesthetized ~-blocked clogs elicit a rapid rise 
in breathing rate, which is reflex in nature as judged by 
the effects of vagal cooling in this system (39). 
This provided a useful model system to study 
breathlessness as it may be driven by activation of RARs, 
but also potentially via airway C-fibres, the activation of 
which has been shown to elicit tachypnoea in the dog 
(11). This histamine-induced tachypnoea was not 
affected by selective ~2-agonists, but was inhibited in a 
dose-dependent manner by sibenadet, yielding an EDs0 of 
0"8 ~g kg- I, following aerosol administration (40). The 
activity of sibenadet in the tachypnoea model lasted for at 
least 4.5 hours, which was the maximum length of time 
the model could be successfully run. At the end of this 
period, its effects were completely reversed by the 
peripherally acting D2-receptor antagonist, domperidone. 
Also in the anaesthetized dog, the effect of sibenadet 
on reflex-induced mucus secretion was investigated 
using a variation of the method of Phipps and Richardson 
(41).Ammonia vapour given to the lungs elicited large 
increases in mucus secretion (as judged by fucose 
output) from an isolated innervated loop of perfused 
trachea. These increases were reduced by cooling the 
vagi prior to ammonia challenge, an effect that could be 
reversed by allowing the vagi to re-warm before a 
subsequent ammonia challenge (42). In the B-blocked 
dog, sibenadet (-  I ~tg kg- I and ~ I 0 I~g kg- I, aerosol) 
inhibited the ammonia-induced increases in mucus in a 
dose-dependent manner (42) with a similar maximal 
efficacy to that of vagal cooling. Sibenadet (5 ~tg kg-I, 
aerosol) also inhibited capsaicin-induced cough in the ~- 
blocked dog (40), a challenge chosen to mimic clinical 
experimental systems (43). 
The effect of sibenadet on capsaicin-induced cough is 
of interest, as there have been recent reports of lowered 
cough thresholds in patients with COPD to citric acid 
challenge (44) as well as capsaicin (45). Sibenadet has 
also been shown to inhibit capsaicin-induced plasma 
extravasation across the trachea of the ~-blocked rat 
(46), an effect reversed by the D2-receptor antagonist, 
sulpiride. This suggests a potential inhibitory activity on 
C-fibre-induced effects. 
Studies conducted with sibenadet in the ~-blocked dog 
to investigate its emetic potential (the emetic effects of a 
number of D 2 agonists are well known) indicated that a 
wide therapeutic window (minimum emetic dose/EDs0 in 
tachypnoea model dose = 39) exists following aerosol 
administration (47). There is also limited emetic 
potential for any swallowed component of the drug, as 
judged by the large dose required to induce emesis by 
the oral route (47). These data, together with the fact 
that sibenadet was optimized for topical delivery to the 
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lung with rapid first pass hepatic clearance, suggested 
that it would have a large safety margin in man. 
When examined in histamine-induced broncho- 
constriction models in both the dog and the guinea-pig, 
sibenadet administered by aerosol was shown to be a 
potent 132-agonist with a long duration of action (greater 
than 10 hours in the dog and greater than 7 hours in the 
guinea-pig) (48). Comparing the EDs0 values obtained 
from the 132 curves obtained in the dog model 
(0"6 p.g kg-I) with those estimated from D 2 curves in the 
dog tachypnoea model (0"8 ~tg kg-I)  demonstrated that 
sibenadet had equivalent potency at both receptors in 
the same species, in vivo. Compounds with different ratios 
of 132 to D 2 activity were also identified during the course 
of our research programme (49). 
Effects of sibenadet on the cough reflex 
in man 
The above pre-clinical studies provided a wealth of data 
on the effects of sibenadet in sensory nerve driven 
animal models that were designed to mimic the 
symptoms of COPE). 
As a link between these studies and the clinical 
programme in patients with COPD, the effects of 
sibenadet on cough, induced by inhalation of nebulized 
distilled water, in human volunteers was investigated. This 
study demonstrated that sibenadet (0.45 mg via pMDI) 
significantly reduced cough in these volunteers (50). 
Given that these volunteers were 13-blocked and that the 
selective D2-receptor antagonist domperidone partially 
reversed the effects of sibenadet, it seemed reasonable to 
speculate that the drug was acting via stimulation of D 2- 
receptors on sensory nerves in the lung. 
CONCLUSIONS 
A range of pre-clinical studies have demonstrated that 
sibenadet is a potent dual D2-receptor and 132- 
adrenoceptor agonist that has a long duration of action 
in the dog following topical delivery to the lung. The 
premise that D2-receptor activation could modulate the 
activity of sensory pulmonary nerves has been 
confirmed and the compound has been shown to be 
effective in a range of reflex-induced models configured 
to mimic the symptoms of breathlessness, excess sputum 
production and cough that afflict patients with COPD. 
These results encouraged the initiation of a clinical 
development programme with sibenadet for the 
symptomatic treatment of COPD. 
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